4.7 Article

Clinical outcomes of 168 Chinese patients after local surgery for bone metastases arising from advanced renal cell carcinoma

Journal

CANCER
Volume 126, Issue -, Pages 2079-2085

Publisher

WILEY
DOI: 10.1002/cncr.32800

Keywords

bone neoplasms; local surgery; renal cell carcinoma; survival rate; treatment outcome

Categories

Ask authors/readers for more resources

Background The effectiveness of local surgery for bone metastases (BM) arising from renal cell carcinoma (RCC) remains uncertain. Herein, the authors performed what to the best of their knowledge is the first investigation of the outcomes of Chinese patients with RCC and BM. Methods Data were collected for 168 patients with RCC and BM who were treated at Changzheng Hospital in Shanghai, China, between March 2009 and December 2018. All patients underwent local surgery for BM arising from RCC. Overall survival (OS) was defined as the interval between the date of local surgery and death or last follow-up and was estimated using the Kaplan-Meier method. Univariate and multivariable Cox proportional hazards analyses were used to identify significant prognostic factors. Results The median OS in the study cohort was 43 months (range, 0-113 months). The 1-year, 3-year, and 5-year survival rates after surgery were 77.4%, 55.9%, and 31.8%, respectively. Univariate analyses demonstrated significant survival differences associated with sex (P = .003), the number of preoperative metastatic sites (BM alone or BM with concomitant metastasis; P < .001), and the number of BM (single or multiple; P = .008). OS also did not appear to differ regardless of whether the patients received postsurgical targeted therapy. Multivariable Cox regression demonstrated that the following characteristics were independent predictors of OS: the number of preoperative metastatic sites, International Metastatic Renal Cell Carcinoma Database Consortium risk score, and Memorial Sloan Kettering Cancer Center score. Conclusions Careful patient selection for local surgery is of paramount importance. The prognoses of patients in the Memorial Sloan Kettering Cancer Center-based and International Metastatic Renal Cell Carcinoma Database Consortium-based poor-risk groups were much worse than those of the intermediate-risk groups. In current clinical practice, stratified treatment can be performed according to these criteria.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Urology & Nephrology

A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)

Zhenjie Wu, Qi Chen, Hooman Djaladat, Andrea Minervini, Robert G. Uzzo, Chandru P. Sundaram, Koon H. Rha, Mark L. Gonzalgo, Reza Mehrazin, Elio Mazzone, Jamil Marcus, Alyssa Danno, James Porter, Aeen Asghar, Fady Ghali, Georgi Guruli, Antoin Douglawi, Giovanni Cacciamani, Alireza Ghoreifi, Giuseppe Simone, Vitaly Margulis, Matteo Ferro, Riccardo Tellini, Andrea Mari, Abhishek Srivastava, James Steward, Ali Al-Qathani, Ahmad Al-Mujalhem, Amit Satish Bhattu, Alexander Mottrie, Firas Abdollah, Daniel D. Eun, Ithaar Derweesh, Alessandro Veccia, Riccardo Autorino, Linhui Wang

Summary: A scoring system based on clinical variables can accurately predict renal insufficiency for cisplatin-based adjuvant chemotherapy after minimally invasive RNU, and it may serve as a tool for patient selection.

EUROPEAN UROLOGY FOCUS (2022)

Review Urology & Nephrology

Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis

Zhenjie Wu, Qi Chen, Le Qu, Mingmin Li, Linhui Wang, Maria C. Mir, Umberto Carbonara, Savio D. Pandolfo, Peter C. Black, Asit K. Paul, Giuseppe Di Lorenzo, Francesco Porpiglia, Andrea Mari, Andrea Necchi, Morgan Roupret, Sarah P. Psutka, Riccardo Autorino

Summary: This study comprehensively investigated the incidence and profile of adverse events associated with immune checkpoint inhibitor therapy in urologic cancer patients. The findings revealed variations in the spectrum and incidence of adverse events across different cancer types, immune checkpoint inhibitor types, clinical settings, and therapy combinations.

EUROPEAN UROLOGY (2022)

Article Urology & Nephrology

Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair tetrafecta Analysis (ROBUUST Collaborative Group)

Alessandro Veccia, Umberto Carbonara, Hooman Djaladat, Reza Mehazin, Daniel D. Eun, Adam C. Reese, Xiaosong Meng, Robert Uzzo, Abhishek Srivastava, James Porter, Jason M. Farrow, Marcus L. Jamil, Giuseppe Rosiello, Riccardo Tellini, Andrea Mari, Ali Al-Qathani, Koon H. Rha, Linhui Wang, Riccardo Mastroianni, Matteo Ferro, Ottavio De Cobelli, Kevin Hakimi, Fabio Crocerossa, Alireza Ghoreifi, Giovanni Cacciamani, Amit S. Bhattu, Alexandre Mottrie, Firas Abdollah, Andrea Minervini, Zhenjie Wu, Giuseppe Simone, Ithaar Derweesh, Mark L. Gonzalgo, Vitaly Margulis, Chandru P. Sundaram, Riccardo Autorino

Summary: Robotic radical nephroureterectomy (RRNU) and laparoscopic radical nephroureterectomy (LRNU) offer comparable outcomes. RRNU is associated with a higher rate of bladder cuff excision, lower overall complications, and shorter length of stay compared to LRNU. LRNU is a negative predictor for achieving tetrafecta outcome.

JOURNAL OF ENDOUROLOGY (2022)

Article Cell Biology

Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis

Aimin Jiang, Yewei Bao, Anbang Wang, Wenliang Gong, Xinxin Gan, Jie Wang, Yi Bao, Zhenjie Wu, Bing Liu, Juan Lu, Linhui Wang

Summary: A prognosis predicting and drug selection model for ccRCC patients was established based on multiomics data analysis, which could accurately predict the prognosis of ccRCC patients and have implications for drug selection.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2022)

Editorial Material Urology & Nephrology

Ureteroscopy and tailored treatment of upper tract urothelial cancer: recent advances and unmet needs

Davide Loizzo, Savio D. Pandolfo, Francesco Del Giudice, Clara Cerrato, Benjamin I. Chung, Zhenjie Wu, Ciro Imbimbo, Pasquale Ditonno, Ithaar Derweesh, Riccardo Autorino

BJU INTERNATIONAL (2022)

Article Urology & Nephrology

Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry

Kevin Hakimi, Umberto Carbonara, Hooman Djaladat, Reza Mehrazin, Daniel Eun, Adam Reese, Mark L. Gonzalgo, Vitaly Margulis, Robert G. Uzzo, James Porter, Chandru P. Sundaram, Firas Abdollah, Alexandre Mottrie, Riccardo Tellini, Matteo Ferro, Arman Walia, Ava Saidian, Shady Soliman, Julia Yuan, Alessandro Veccia, Alireza Ghoreifi, Giovanni Cacciamani, Amit S. Bhattu, Xiaosong Meng, Jason M. Farrow, Marcus Jamil, Andrea Minervini, Koon H. Rha, Zhenjie Wu, Giuseppe Simone, Riccardo Autorino, Ithaar H. Derweesh

Summary: This study evaluated the outcomes of lymph node dissection in patients with upper tract urothelial carcinoma, finding that the procedure did not improve overall survival but was associated with improved recurrence-free survival in patients with clinical node negative disease and when yielding a higher number of lymph nodes.

JOURNAL OF UROLOGY (2022)

Review Urology & Nephrology

Robotic ureteral reimplantation: systematic review and pooled analysis of comparative outcomes in adults

Umberto Carbonara, Fabio Crocerossa, Reza Mehrazin, Riccardo Campi, Michele Marchioni, Alessandro Morlacco, Vincenzo Paglairulo, Zhenjie Wu, Riccardo Autorino, Robert J. Stein, Daniel Eun, Pasquale Ditonno, Fabrizio Dal Moro

Summary: The current systematic review indicates that robot-assisted ureteral reimplantation (RAUR) offers similar surgical outcomes compared to open ureteral reimplantation (OUR), with potential advantages in terms of lower blood loss, shorter hospital stay, catheter, and stent time.

MINERVA UROLOGY AND NEPHROLOGY (2022)

Article Urology & Nephrology

Single-stage Xi® robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes

Alessandro Veccia, Umberto Carbonara, Ithaar Derweesh, Reza Mehrazin, James Porter, Firas Abdollah, Elio Mazzone, Chandru P. Sundaram, Mark Gonzalgo, Riccardo Mastroianni, Alireza Ghoreifi, Giovanni E. Cacciamani, Devin Patel, Jamil Marcus, Alyssa Danno, James Steward, Amit Satish Bhattu, Aeen Asghar, Adam C. Reese, Zhenjie Wu, Robert G. Uzzo, Andrea Minervini, Koon H. Rha, Matteo Ferro, Vitaly Margulis, Lance J. Hampton, Giuseppe Simone, Daniel D. Eun, Hooman Djaladat, Alexandre Mottrie, Riccardo Autorino

Summary: This article describes the surgical steps and outcomes of Xi (R) robotic RNU. The study found that this minimally invasive procedure is reproducible and safe for treating UTUC.

MINERVA UROLOGY AND NEPHROLOGY (2022)

Article Andrology

A comparison of perioperative outcomes between extraperitoneal robotic single-port and multiport radical prostatectomy with the da Vinci Si Surgical System

Guan-Qun Ju, Zhi-Jun Wang, Jia-Zi Shi, Zong-Qin Zhang, Zhen-Jie Wu, Lei Yin, Bing Liu, Lin-Hui Wang, Dong-Liang Xu

Summary: The study compared outcomes of extraperitoneal robotic single-port radical prostatectomy and extraperitoneal robotic multiport radical prostatectomy, and found differences in operative time, estimated blood loss, and postoperative recovery between the two groups, with single-port surgery showing advantages in certain aspects and being a viable treatment option.

ASIAN JOURNAL OF ANDROLOGY (2021)

Article Urology & Nephrology

Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration)

Andrew B. Katims, Rollin Say, Ithaar Derweesh, Robert Uzzo, Andrea Minervini, Zhenjie Wu, Firas Abdollah, Chandru Sundaram, Matteo Ferro, Koon Rha, Alex Mottrie, Giuseppe Rosiello, Giuseppe Simone, Daniel D. Eun, Adam Reese, Laura C. Kidd, James Porter, Amit Satish Bhattu, Mark L. Gonzalgo, Vitaly Margulis, Jamil Marcus, Alyssa Danno, Margaret Meagher, Riccardo Tellini, Andrea Mari, Alessandro Veccia, Alireza Ghoreifi, Riccardo Autorino, Hooman Djaladat, Reza Mehrazin

Summary: The study analyzed 485 patients with UTUC who underwent minimally invasive RNU and found that IVR is a relatively common event after the procedure. Risk factors include hypertension, diagnostic ureteroscopic biopsy, positive surgical margins, and transurethral resection for bladder cuff management. Avoiding certain procedures and considering alternative strategies for obtaining biopsy tissue samples may help reduce the risk of IVR.

JOURNAL OF UROLOGY (2021)

Article Biochemistry & Molecular Biology

DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma

Yewei Bao, Aimin Jiang, Kai Dong, Xinxin Gan, Wenliang Gong, Zhenjie Wu, Bing Liu, Yi Bao, Jie Wang, Linhui Wang

Summary: The increased expression of DDX39 in ccRCC patients predicted worse clinical prognosis, promoted ccRCC cell proliferation, migration, and invasion, and also predicted adverse efficacy of immune checkpoint therapy.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

Article Urology & Nephrology

Pure retroperitoneoscopic extravesical standardized seeable (PRESS) excision of distal ureter and bladder cuff in radical nephroureterectomy: step-by-step technique

Zhenjie Wu, Mingmin Li, Jianchao Wang, Alessandro Veccia, Yifan Xu, Chao Zhang, Jizhong Ren, Lei Yin, Ming Chen, Junkai Wang, Dongliang Xu, Zongqin Zhang, Bing Liu, Bo Yang, Liping Xie, Le Qu, Linhui Wang

Summary: The study demonstrated a modified retroperitoneoscopic RNU technique that is safe and reproducible, achieving complete BCE and facilitating LND. Goals in minimally invasive RNU should include achieving BCE trifecta. Prospective comparison with open surgical technique is needed.

MINERVA UROLOGY AND NEPHROLOGY (2021)

Article Multidisciplinary Sciences

Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells

Yicun Wang, Jinhui Wu, Hui Chen, Yang Yang, Chengwu Xiao, Xiaoming Yi, Changjie Shi, Ke Zhong, Haowei He, Yaoming Li, Zhenjie Wu, Guangxin Zhou, Qiu Rao, Xiaoxia Wang, Xiaodie Zhou, Gwen Lomberk, Bing Liu, Jianning Zhao, Jingping Ge, Wenquan Zhou, Xiaoyuan Chu, Cheng Chen, Xuhui Zhou, Linhui Wang, Kunliang Guan, Le Qu

Summary: The study identified KLF11 as a negative regulator in sarcoma cancer stem cells, forming a negative feedback loop with YAP/TEAD. Epigenetic silencing of KLF11 in CSCs leads to sustained YAP activation, which is associated with poor prognosis and chemotherapy response in sarcoma patients. Pharmacological activation of KLF11 effectively restored chemotherapy response.

SCIENCE ADVANCES (2021)

No Data Available